Company intelligence / Profile preview

4Living Biotech

Ownership: Private
Development stage: Phase 2

Overview

4Living Biotech was conducting a Phase 2b clinical trial called LEONARDO to evaluate the efficacy and safety of Plerixafor in patients with acute respiratory failure related to COVID-19. The trial was designed as a multicenter, randomized, double-blind, placebo-controlled, parallel group study for patients over 18 years of age. The company received approval from the French National Agency for Medicinal Products (ANSM) and two other European agencies to initiate this trial[7]. However, the trial status was listed as "Withdrawn" as of May 2025[2].

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (Plerixafor)
Industry: Biotech

Drug pipeline

1 asset

4P021

Preclinical

Partnerships

Sanofi

Beyond the preview

Go deeper on 4Living Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4Living Biotech.

Explore the full profile